A study on determinants of underreporting of adverse drug reactions among resident doctors
DOI:
https://doi.org/10.18203/2320-6012.ijrms20180310Keywords:
ADR, Pharmacovigilance, Resident doctors, UnderreportingAbstract
Background: Adverse Drug Reactions (ADRs) are global problem with significant morbidity and mortality. Health care providers/professionals (HCPs) play a critical role in ADR surveillance. However, only 6% of all ADRs are reported and under-reporting acts as great impedance in exchange of drug information. Thus, spontaneous reporting of suspected adverse drug reactions requires greater commitment from healthcare professionals. The aim was to determine the reasons of underreporting of ADRs among resident doctors.
Methods: This was a cross-sectional observational study with self-administered questionnaire assessing the reasons for underreporting of ADRs among resident doctors.
Results: Very low level of awareness about ADR reporting was found among doctors. Eighty eight percent of doctors did not know the authority and the procedure for ADR reporting. About 32.8% were not sure with the reaction and the drug, while 46.3% doctors felt that there is no need of reporting the recognized reactions again. Other factors responsible for under reporting were lack of time in 73% and cumbersome procedure in 45% of the participants.
Conclusions: A poor level of awareness of pharmacovigilance was seen among doctors. Measure to improve awareness, accessible systems for reporting and effective National Programme are required to improve reporting
References
Wu WK, Pantaleo N. Evaluation of outpatient adverse drug reactions leading to hospitalization. Ame J Health-System Pharm. 2003;60(3):253-9.
World Health Organization. International drug monitoring: The role of national centres. Report of a WHO meeting. World Health Organ Tech Rep Ser. 1972;498:1-25.
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-9.
Rodriguez-Monguio R, Otero MJ, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics. 2003;21(9):623-50.
Einarson TR. Drug-related hospital admissions. Ann Pharmacother. 1993;27:832-40.
Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a South Indian hospital-their severity and cost involved. Pharmacoepidemiol Drug Saf. 2003;12:687-92.
ASHP guidelines on adverse drug reaction monitoring and reporting. Am J Health Syst Pharm. 1995;52:140-2
World Health Report, 2006. Available at http://www.who.int/whr/2006/en/ accessed on 28th August 2009.
Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions. Drug safety. 2009;32(1):19-31.
Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJ, Aronson JK, GRAHAME‐SMITH DG. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Brit J Clin Pharmacol. 1996;42(4):423-9.
Prakash S. Pharmacovigilance in India. Indian J Pharmacology. 2007;39(3).
Pushkin R, Frassetto L, Tsourounis C, Segal ES, Kim S. Improving the reporting of adverse drug reactions in the hospital setting. Postgraduate medicine. 2010;122(6):154-64.
Irujo M, Beitia G, Bes-Rastrollo M, Figueiras A, Hernandez-Diaz S, Lasheras B. Factors that influence underreporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Saf. 2007;30:1073-82.
Hazell L, Shakir SA. Under-reporting of adverse drug reactions: A systematic review. Drug Saf. 2006;29:385-96.
Khan SA, Goyal C, Chandel N, Rafi M. Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: An observational study. J Nat Sci Biol Med. 2013;4:191-6.
Klopotowska JE, Wierenga PC, Smorenburg SM, Stuijt CC, Arisz L, Kuks PF, et al. Recognition of adverse drug events in older hospitalized medical patients. Eur J Clin Pharmacol. 2013;69:75-85.
Khan LM, Al-Harthi SE, Saadah OI. Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR. Saudi Pharm J. 2013;21:261-6.
Goldstein LH, Berlin M, Saliba W, Elias M, Berkovitch M. Founding an adverse drug reaction (ADR) network: A method for improving doctor’s spontaneous ADR reporting in a general hospital. J Clin Pharmacol. 2013;53:1220-5.
Inch J, Watson MC, Anakwe-Umeh S. Patient versus healthcare professional spontaneous adverse drug reaction reporting: A systematic review. Drug Saf. 2012;35:807-18.
Adams SA. Using patient-reported experiences for pharmacovigilance? Stud Health Technol Inform. 2013;194:63-8.
Griffith R. Nurses must report adverse drug reactions. Br J Nurs. 2013;22:484-5.
Santosh KC, Tragulpiankit P, Edwards IR, Gorsanan S. Knowledge about adverse drug reactions reporting among healthcare professionals in Nepal. Int J Risk Saf Med. 2013;25:1-16.
Pérez García M, Figueras A. The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: Direct survey among health professionals. Pharmacoepidemiol Drug Saf. 2011;20:1295-302.
Herdeiro MT, Ribeiro-Vaz I, Ferreira M, Polónia J, Falcão A, Figueiras A. Workshop- and telephone-based interventions to improve adverse drug reaction reporting: A cluster-randomized trial in Portugal. Drug Saf. 2012 1;35:655-65.
Rehan HS, Vasudev K, Tripathi CD. Adverse drug reaction monitoring: Knowledge, attitude and practices of medical students and prescribers. Natl Med J India. 2002;15:24-6.
Vora MB, Paliwal NP, Doshi VG, Barvaliya MJ, Tripathi CB. Knowledge of adverse drug reactions and pharmavovigilance activity among the undergraduate students of Gujarat. Int J Pharm Sci Res. 2012;1511-5.
Mariam Molokhia, Shivani Tanna, Derek Bell. Systematic Rev Clin Epidemiol. 2009:175-92.
Organization WH, others. Pharmacovigilance: ensuring the safe use of medicines, 2004. Available at http://apps.who.int/iris/handle/10665/68782.
Kumar L. Pharmacovigilance/reporting adverse drug reactions: an approach to enhance health surveillance and extending market share by minimizing the chances of drug withdrawals. Int J Pharm Pharmceu Sci. 2015;7:1-7.
Hardeep JK, Rakesh K. A survey on the knowledge, attitude and the practice of pharmacovigilance among the health care professionals in a teaching hospital in northern India. J Clin Diag Res: JCDR. 2013;7(1):97.
Gonzalez EL, Herdeiro MT, Figueiras A. Determinants of Under-Reporting of Adverse Drug Reactions: A Systematic Review. Drug Saf. 2009;32(1):19-31.
Perlik F, Slanar O, Smid M, Petracek. Attitude of Czech physicians to adverse drug reaction reporting. Eur J Clin Pharmacol. 2002;58: 367-9.
Gupta P, Udupa A. Adverse drug reaction reporting and pharmacovigilance: Knowledge, attitudes and perceptions amongst resident doctors. J Pharm Sci Res. 2011;3(2):1064-9.
Bracchi RC, Houghton J, Woods FJ, Thomas S, Smail SA, Routledge PA. A distance‐learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme. Brit J Clin Pharmacol. 2005;60(2):221-3.
Scott HD, Thacher-Renshaw A, Rosenbaum SE, Waters WJ, Green M, Andrews LG, et al. Physician reporting of adverse drug reactions: results of the Rhode Island adverse drug reaction reporting project. JAMA. 1990;263(13):1785-8.
